{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:43:10Z","timestamp":1789879390380,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jinf.2014.06.003","type":"journal-article","created":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T18:51:46Z","timestamp":1402599106000},"page":"375-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["No evidence for a protective effect of naturally induced HPV antibodies on subsequent anogenital HPV infection in HIV-negative and HIV-infected MSM"],"prefix":"10.1016","volume":"69","author":[{"given":"Sofie H.","family":"Mooij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Land\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona R.M.","family":"van der Klis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne A.B.","family":"van der Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel A.","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"van Eeden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn S.","family":"van Rooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.L.M.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten F.","family":"Schim van der Loeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 10","key":"10.1016\/j.jinf.2014.06.003_bib1","doi-asserted-by":"crossref","first-page":"K17","DOI":"10.1016\/j.vaccine.2008.06.021","article-title":"Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions","volume":"26","author":"Giuliano","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jinf.2014.06.003_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens \u2013 part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jinf.2014.06.003_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-9378-5-19","article-title":"HPV \u2013; immune response to infection and vaccination","volume":"5","author":"Stanley","year":"2010","journal-title":"Infect Agent Cancer"},{"issue":"12","key":"10.1016\/j.jinf.2014.06.003_bib4","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1172\/JCI57149","article-title":"The known unknowns of HPV natural history","volume":"121","author":"Gravitt","year":"2011","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.jinf.2014.06.003_bib5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/jmv.23616","article-title":"Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme","volume":"85","author":"Mollers","year":"2013","journal-title":"J Med Virol"},{"issue":"9447","key":"10.1016\/j.jinf.2014.06.003_bib6","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"27\u201328","key":"10.1016\/j.jinf.2014.06.003_bib7","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl. 5","key":"10.1016\/j.jinf.2014.06.003_bib8","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jinf.2014.06.003_bib9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jinf.2014.06.003_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1470-2045(12)70080-3","article-title":"Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis","volume":"13","author":"Machalek","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jinf.2014.06.003_bib11","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1200\/JCO.2012.44.5486","article-title":"Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV","volume":"30","author":"Piketty","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jinf.2014.06.003_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAD.0b013e328342fbe9","article-title":"Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study","volume":"25","author":"Jansen","year":"2011","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.jinf.2014.06.003_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/sti.2008.033258","article-title":"Opting out increases HIV testing in a large sexually transmitted infections outpatient clinic","volume":"85","author":"Heijman","year":"2009","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.jinf.2014.06.003_bib14","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1097\/01.aids.0000432541.67409.3c","article-title":"Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM","volume":"27","author":"van Aar","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2014.06.003_bib15","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1097\/QAD.0b013e328362395c","article-title":"Oral human papillomavirus infection in HIV-negative and HIV-infected men who have sex with men: the HIV & HPV in MSM (H2M) study","volume":"27","author":"Mooij","year":"2013","journal-title":"AIDS"},{"issue":"47","key":"10.1016\/j.jinf.2014.06.003_bib16","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1016\/j.vaccine.2012.08.068","article-title":"Seroprevalence of seven high-risk HPV types in The Netherlands","volume":"30","author":"Scherpenisse","year":"2012","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.jinf.2014.06.003_bib17","doi-asserted-by":"crossref","first-page":"e74797","DOI":"10.1371\/journal.pone.0074797","article-title":"Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses","volume":"8","author":"Scherpenisse","year":"2013","journal-title":"PLoS One"},{"issue":"1\u20132","key":"10.1016\/j.jinf.2014.06.003_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J Immunol Methods"},{"issue":"9","key":"10.1016\/j.jinf.2014.06.003_bib19","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1128\/JCM.00539-06","article-title":"Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR","volume":"44","author":"Van Doorn","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.jinf.2014.06.003_bib20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1158\/1055-9965.EPI-09-0546","article-title":"Marginal and mixed-effects models in the analysis of human papillomavirus natural history data","volume":"19","author":"Xue","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"10.1016\/j.jinf.2014.06.003_bib21","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1055-9965.EPI-13-0460","article-title":"Seroepidemiology of high-risk HPV in HIV-negative and HIV-infected MSM: the H2M Study","volume":"22","author":"Mooij","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.jinf.2014.06.003_bib22","doi-asserted-by":"crossref","first-page":"e53067","DOI":"10.1371\/journal.pone.0053067","article-title":"HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jinf.2014.06.003_bib23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/vim.2009.0055","article-title":"Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV","volume":"22","author":"Malik","year":"2009","journal-title":"Viral Immunol"},{"issue":"21","key":"10.1016\/j.jinf.2014.06.003_bib24","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/jnci\/djq384","article-title":"Epidemiological study of anti-HPV16\/18 seropositivity and subsequent risk of HPV16 and -18 infections","volume":"102","author":"Safaeian","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.jinf.2014.06.003_bib25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/342972","article-title":"Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles","volume":"186","author":"Ho","year":"2002","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2014.06.003_bib26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1055-9965.EPI-03-0166","article-title":"Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica","volume":"13","author":"Viscidi","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.jinf.2014.06.003_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/1055-9965.283.14.1","article-title":"Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women","volume":"14","author":"Viscidi","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.jinf.2014.06.003_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1055-9965.EPI-09-0790","article-title":"Epidemiologic factors associated with seropositivity to human papillomavirus type 16 and 18 virus-like particles and risk of subsequent infection in men","volume":"19","author":"Lu","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.jinf.2014.06.003_bib29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1158\/0008-5472.CAN-11-0751","article-title":"Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men","volume":"72","author":"Lu","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jinf.2014.06.003_bib30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2334-14-120","article-title":"Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus","volume":"14","author":"Robbins","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"9","key":"10.1016\/j.jinf.2014.06.003_bib31","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1055-9965.EPI-12-0483","article-title":"Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men","volume":"21","author":"Lu","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"10.1016\/j.jinf.2014.06.003_bib32","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/infdis\/jit295","article-title":"Route of sexual exposure is independently associated with seropositivity to HPV-16 and HPV-18 among clients of an STI clinic in the Netherlands","volume":"208","author":"Heiligenberg","year":"2013","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2014.06.003_bib33","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/hv.22693","article-title":"Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination","volume":"9","author":"Scherpenisse","year":"2012","journal-title":"Hum Vaccin Immunother"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445314001625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445314001625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:20:12Z","timestamp":1759008012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445314001625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0163445314001625"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2014.06.003","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No evidence for a protective effect of naturally induced HPV antibodies on subsequent anogenital HPV infection in HIV-negative and HIV-infected MSM","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2014.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}